about

Group Overview

We have a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products.

As a leading global player in specialty, branded and generic pharmaceuticals, we have an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. We continue to increase the number of lives benefiting from our products that reach more than 150 countries. In line with the our commercial, production and territorial strategies, we have identified Thrombosis, Anaesthetics, High Potency & Cytotoxics and Nutritionals as our focused therapeutic categories that will receive our highest focus based on materiality and future potential.

We hold international manufacturing approvals from some of the most stringent global regulatory agencies listed here including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines. Our manufacturing capabilities are scaleable to demand and cover a wide variety of product types including oral solid dose, liquids, semi-solids, steriles, biologicals, active pharmaceutical ingredients and nutritionals.

GLOBAL PRESENCE

Aspen has a strong presence in both emerging and developed countries with more than ​​​​​​​60 established business operations in approximately 50 countries. The Group supplies medicines and products to more than 150 countries.

globalpresence

THE ASPEN TIMELINE

timeline

Quick Facts

Established: 1850
Employees: + 10 000
Market capitalisation: US$10 billion
Share code: APN
JSE: Top 20 on this exchange 

Board of Directors

Stephen Saad (53)

Stephen Saad (53)

Qualification:
CA(SA), Honorary doctorate
Appointment: January 1999
Classification: Executive director; Aspen Group Chief Executive

Gus Attridge (56)

Gus Attridge (56)

Qualification:
 CA(SA)
Appointment: January 1999
Classification: Executive director; Deputy Group Chief Executive

Kuseni Dlamini (49)

Kuseni Dlamini (49)

Qualification:
 MPhil (Oxon), BSocSci (Hons), (Natal) (see full CV's)
Appointment: April 2012
Classification: Independent non-executive, Chairman

Roy Andersen (69)

Roy Andersen (69)

Qualification:
 CA(SA), CPA (Texas), CD(SA)
Appointment: August 2008
Classification: Lead independent non-executive

John Buchanan (73)

John Buchanan (73)

Qualification: 
CA(SA), BTh (Hons) EDP (Columbia)
Appointment: May 2002
Classification: Independent non-executive

Chris Mortimer (56)

Chris Mortimer (56)

Qualification: 
BA, LLB
Appointment: January 1999
Classification: Non-executive

Babalwa Ngonyama (43)

Babalwa Ngonyama (43)

Qualification:
 CA(SA), MBA, Higher Diploma in Banking Law (RAU)
Appointment: April 2016
Classification: Independent non-executive

David Redfern (51*)

David Redfern (51*)

Qualification: 
BSc (Hons), CA
Appointment: February 2015
Classification:Non-executive
*British

Sindi Zilwa (50)

Sindi Zilwa (50)

Qualification:
 CA(SA), CDSA, Advanced Taxation (UNISA) Certificate (see CV's)
Appointment: September 2006
Classification: Independent non-executive

Business Segment Overview

Anaesthetics

anasthetics
anasthetics

Revenue

R7,0 billion

17%

of total revenue

KEY BRANDS
  • Diprivan
  • EMLA
  • Naropin
  • Ultiva
  • Xylocaine

Thrombosis

thrombosis
thrombosis

Revenue

R5,7 billion

14%

of total revenue

KEY BRANDS
  • Arixtra
  • Fraxiparine
  • Mono-embolex
  • Orgaran

High potency & cytotosic

hpcyto
hpcyto

Revenue

R4,7 billion

11%

of total revenue

KEY BRANDS
  • Alkeran
  • Eltroxin
  • Imuran
  • Ovestin
  • Purinethol

Nutritionals

nutritionals
nutritionalicon

Revenue

R3,2 billion

8%

of total revenue

KEY BRANDS
  • Alula
  • Infacare
  • S-26
  • SMA